<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4488">
  <stage>Registered</stage>
  <submitdate>12/06/2014</submitdate>
  <approvaldate>12/06/2014</approvaldate>
  <nctid>NCT02164435</nctid>
  <trial_identification>
    <studytitle>Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation</studytitle>
    <scientifictitle>Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation</scientifictitle>
    <utrn />
    <trialacronym>RDN</trialacronym>
    <secondaryid>CI-12-044-AU-HT</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Uncontrolled Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Renal Denervation (EnligHTN) Renal artery ablation with the EnligHTN Renal Denervation System.

Other: Renal Denervation - 


Treatment: surgery: Renal Denervation (EnligHTN) Renal artery ablation with the EnligHTN Renal Denervation System.


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cardiac Function (evaluated by MRI) - MRI Indices of Cardiac Function
Myocardial mass and myocardial fibrosis
Atrial and ventricular ejection function
Myocardial perfusion
Arterial distensibility</outcome>
      <timepoint>Baseline and 6 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Function (evaluated by MRI) - MRI Indices of Renal Function:
Renal blood flow
Renal perfusion
Urinary protein</outcome>
      <timepoint>Baseline, 6 Months and 24 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiac Function - MRI Indices of Cardiac Function
Myocardial mass and myocardial fibrosis
Atrial and ventricular ejection function
Myocardial perfusion
Arterial distensibility</outcome>
      <timepoint>Baseline and 24 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must be able and willing to comply with the required follow-up schedule

          -  Therapeutic Goods Association approved indications for EnligHTN Renal Denervation
             System

          -  Subject is = 18 years of age at time of consent Subject has office SBP = 160 mmHg
             (except for subjects with Diabetes Mellitus who must demonstrate an office SBP of =
             150 mm Hg) within 14 days of the procedure ?Subject is taking = 3 antihypertensive
             medications concurrently at maximum tolerated dose (this must include one diuretic) or
             subject has a documented intolerance to at least 2 out of the 4 major classes of
             anti-hypertensives (ACE/ARB, CCB, Diuretics, Beta Blockers and is unable to take 3
             antihypertensive drugs.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Standard CMR exclusions;

               -  implanted cardiac device

               -  intracranial metallic implants

               -  claustrophobia -Gadolinium-specific: estimated GFR &lt;60 mls/min (usual clinical
                  cut-off is &lt;30 mls/min).

          -  Adenosine-specific:

               -  asthma / reactive airways disease

               -  &gt;first degree atrioventricular block

               -  concomitant use of dipyridamole or theophylline consumption of caffeine within 48
                  hours of proposed investigation

               -  EnligHTN Renal Denervation System exclusion criteria:

        Subject has an identified cause of secondary hypertension

          -  Subject has an estimated GFR &lt;45 mL/min per 1.73 m2 using the MDRD formula

          -  Subject has undergone prior renal angioplasty, indwelling renal stents, and/or aortic
             stent grafts

          -  Subject has haemodynamically significant valvular heart disease

          -  Subject has a life expectancy less than 12 months, as determined by the PI

          -  Subject is participating in another clinical study Subject is pregnant, nursing, or of
             childbearing potential and is not using adequate contraceptive methods

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital Adelaide - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Adelaide</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, single centre clinical investigation looking at short (6 months) and
      long term (24 months) changes in cardiac function and renal function in patients with
      drug-resistant hypertension post renal sympathetic denervation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02164435</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Stephen G Worthley, Prof</name>
      <address />
      <phone />
      <fax />
      <email>stephen.worthley@adelaide.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>